Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TRAP Clear all
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT00943072
View directory record Official record
Conditions
Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions
VEGF Trap-Eye 2.0mg, Sham
Biological · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 20, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions
MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
Biological · Drug
Lead sponsor
Memgen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Tampa, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

NCT00396591
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

VEGF Trap in Treating Patients With Metastatic Breast Cancer

NCT00369655
View directory record Official record
Conditions
Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

NCT03620201
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Bintrafusp Alfa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 20, 2026, 5:38 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

R4Power: An Online Resilience Program for Adolescents

NCT00641368
View directory record Official record
Conditions
Depression, Anxiety
Interventions
R4Power Program, Waitlist Control
Behavioral · Other
Lead sponsor
Swarthmore College
Other
Eligibility
11 Years to 15 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Swarthmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Results available

First in Human Study of M6223

NCT04457778
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
M6223, Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

NCT04708067
View directory record Official record
Conditions
Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Bintrafusp Alfa, Biopsy, Hypofractionated Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lung-Resident Memory Th2 Cells in Asthma

NCT03455959
View directory record Official record
Conditions
Asthma, Allergic
Interventions
Bronchoscopy/BAL, Airway Brushing
Procedure
Lead sponsor
Andrew D. Luster, M.D.,Ph.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Terminated Not applicable Interventional

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054
View directory record Official record
Conditions
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
Up to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

EndoRotor® Endoscopic Mucosal Resection System for the Colon

NCT04203667
View directory record Official record
Conditions
Polyp of Colon, Endoscopic Mucosal Resection, Recurrent Colon Adenoma
Interventions
EndoRotor Resection
Device
Lead sponsor
Interscope, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 20, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

NCT00265200
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
Interventions
zoledronic acid
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 20, 2026, 5:38 AM EDT
Suspended Phase 1 Interventional

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

NCT05076591
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Interventions
IMM2902
Drug
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 20, 2026, 5:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

NCT01663103
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 20, 2026, 5:38 AM EDT
Withdrawn Phase 2 Interventional

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

NCT00609544
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Rilonacept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Alexander City, Alabama • Muscle Shoals, Alabama • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT00320788
View directory record Official record
Conditions
Macular Degeneration
Interventions
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1Phase 2 Interventional

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

NCT01189383
View directory record Official record
Conditions
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Interventions
IL15-DC Vaccine
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Study for Recalcitrant Age Related Macular Degeneration

NCT01543568
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
aflibercept 2.0 mg
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 20, 2026, 5:38 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT07732686
View directory record Official record
Conditions
Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon Cancer, Bladder Cancer, Other Cancer
Interventions
Proton Transfer Reaction Mass Spectrometry Analysis
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 5:38 AM EDT
Not listed No phase listed Observational

Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders

NCT00004341
View directory record Official record
Conditions
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

NCT00320814
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
VEGF Trap-Eye
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 20, 2026, 5:38 AM EDT
Not listed Phase 4 Interventional

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 20, 2026, 5:38 AM EDT